Skip to content

Abstract 8000: Polygenic Risk Identifies Early-Life LDL-C Elevation and Highlights Treatment Opportunities in a U.S. Clinical Population

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: Hypercholesterolemia (HC) is a major driver of cumulative atherosclerotic cardiovascular disease (ASCVD) risk across the lifespan. While polygenic risk scores (PRS) for HC may complement monogenic familial hypercholesterolemia (FH) testing, their relationship to early-life LDL-C burden and clinical management remains unclear. Methods: We analyzed genetic and electronic health record data from 19,602 adult (18-75 yrs, mean 50.6) and 4,251 pediatric (3-17 years, mean 11.7) participants enrolled across 10 U.S. clinical sites in the Electronic Medical Records and Genomics IV study. Adults were classified as monogenic FH (FH+; n=139; 0.7%), high (top 3%) PRS (PRS+; n=412; 2.1%), or “not-high-risk” (NHR; n=19,051; 97.2%). The same PRS were calculated in children (n=81 with high HC PRS; children did not have monogenic testing). We performed replication analyses in an age-matched cohort from the All of Us Research Program v8 (AoU; n=361,475; 2.2% PRS+). Results: We observed higher LDL-C levels in the PRS+ group vs. the NHR group beginning in childhood (mean 104 vs 89 mg/dL; p=0.004), peaking between ages 26-35 (137 vs 102 mg/dL; p=1x10-12), and persisting throughout adulthood until age 65. For comparison, FH+ was also associated with higher LDL-C in early life (e.g. 26-35 yrs: 149 mg/dL). PRS+ had higher rates of lipid disorder diagnoses across all age bins (overall rate ratio: 1.4; p=1x10-30) but no significant increase in lipid-lowering therapy prescriptions until ages 36-45. In contrast, FH+ were 5.5 times more likely to have a prescription by ages 26-35 (p=5x10-10). Among all 4,250 treated adults, PRS+ were 42% less likely and FH+ were 70% less likely to achieve LDL-C under 100 mg/dL (p=0.003 and p=9x10-5, respectively) vs. the NHR group. Findings replicated independently in AoU, where PRS+ had higher LDL-C (e.g. 26-35 yrs: 119 vs 100 mg/dL), increased HC diagnosis rates, delayed lipid-lowering therapy initiation, and were 23% less likely to achieve LDL-C under 100 mg/dL when treated (p=6x10-9). Conclusions: Our findings reveal elevated LDL-C since childhood and a potential systematic delay of treatment for PRS-defined HC risk compared to FH across the life course. This highlights an opportunity to identify high-risk individuals earlier and implement more timely lipid-lowering interventions to reduce ASCVD burden through the integration of HC PRS in clinical practice.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.